vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and McEwen Inc. (MUX). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $64.6M, roughly 1.2× McEwen Inc.). McEwen Inc. runs the higher net margin — 59.0% vs -9.6%, a 68.6% gap on every dollar of revenue. On growth, McEwen Inc. posted the faster year-over-year revenue change (92.8% vs -16.8%). Over the past eight quarters, McEwen Inc.'s revenue compounded faster (25.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

McEwen Inc (ticker MUX) is a natural resource company primarily engaged in the exploration, development, and production of gold, silver, and copper assets. Its core operations are located across North and South America, serving global commodity markets with a focus on sustainable, responsible mining practices.

BIOX vs MUX — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.2× larger
BIOX
$77.6M
$64.6M
MUX
Growing faster (revenue YoY)
MUX
MUX
+109.6% gap
MUX
92.8%
-16.8%
BIOX
Higher net margin
MUX
MUX
68.6% more per $
MUX
59.0%
-9.6%
BIOX
Faster 2-yr revenue CAGR
MUX
MUX
Annualised
MUX
25.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
MUX
MUX
Revenue
$77.6M
$64.6M
Net Profit
$-7.4M
$38.1M
Gross Margin
46.8%
26.9%
Operating Margin
9.3%
34.2%
Net Margin
-9.6%
59.0%
Revenue YoY
-16.8%
92.8%
Net Profit YoY
-20.2%
563.1%
EPS (diluted)
$-0.12
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
MUX
MUX
Q4 25
$64.6M
Q3 25
$77.6M
$50.5M
Q2 25
$46.7M
Q1 25
$60.6M
$35.7M
Q4 24
$98.8M
$33.5M
Q3 24
$93.3M
$52.3M
Q2 24
$47.5M
Q1 24
$84.0M
$41.2M
Net Profit
BIOX
BIOX
MUX
MUX
Q4 25
$38.1M
Q3 25
$-7.4M
$-462.0K
Q2 25
$3.0M
Q1 25
$-1.6M
$-6.3M
Q4 24
$605.2K
$-8.2M
Q3 24
$-6.2M
$-2.1M
Q2 24
$-13.0M
Q1 24
$9.8M
$-20.4M
Gross Margin
BIOX
BIOX
MUX
MUX
Q4 25
26.9%
Q3 25
46.8%
15.5%
Q2 25
26.3%
Q1 25
39.4%
28.2%
Q4 24
42.0%
1.1%
Q3 24
40.2%
26.4%
Q2 24
22.7%
Q1 24
50.8%
14.6%
Operating Margin
BIOX
BIOX
MUX
MUX
Q4 25
34.2%
Q3 25
9.3%
-16.7%
Q2 25
-7.2%
Q1 25
1.5%
-21.4%
Q4 24
14.5%
-43.4%
Q3 24
2.5%
-0.2%
Q2 24
-29.4%
Q1 24
15.7%
-53.3%
Net Margin
BIOX
BIOX
MUX
MUX
Q4 25
59.0%
Q3 25
-9.6%
-0.9%
Q2 25
6.5%
Q1 25
-2.6%
-17.6%
Q4 24
0.6%
-24.6%
Q3 24
-6.6%
-4.0%
Q2 24
-27.4%
Q1 24
11.6%
-49.4%
EPS (diluted)
BIOX
BIOX
MUX
MUX
Q4 25
$0.66
Q3 25
$-0.12
$-0.01
Q2 25
$0.06
Q1 25
$-0.02
$-0.12
Q4 24
$0.00
$-0.15
Q3 24
$-0.10
$-0.04
Q2 24
$-0.26
Q1 24
$0.14
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
MUX
MUX
Cash + ST InvestmentsLiquidity on hand
$15.5M
$72.1M
Total DebtLower is stronger
$126.2M
Stockholders' EquityBook value
$288.3M
$546.2M
Total Assets
$734.9M
$820.2M
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
MUX
MUX
Q4 25
$72.1M
Q3 25
$15.5M
$75.4M
Q2 25
$69.5M
Q1 25
$38.5M
$79.3M
Q4 24
$29.2M
$15.3M
Q3 24
$32.3M
$30.2M
Q2 24
$42.6M
Q1 24
$16.4M
$22.0M
Total Debt
BIOX
BIOX
MUX
MUX
Q4 25
$126.2M
Q3 25
$126.0M
Q2 25
$125.8M
Q1 25
$125.5M
Q4 24
$40.0M
Q3 24
$31.0M
Q2 24
$34.0M
Q1 24
$37.0M
Stockholders' Equity
BIOX
BIOX
MUX
MUX
Q4 25
$546.2M
Q3 25
$288.3M
$488.6M
Q2 25
$484.5M
Q1 25
$345.0M
$479.8M
Q4 24
$346.3M
$495.0M
Q3 24
$346.0M
$502.1M
Q2 24
$485.2M
Q1 24
$348.5M
$482.5M
Total Assets
BIOX
BIOX
MUX
MUX
Q4 25
$820.2M
Q3 25
$734.9M
$747.6M
Q2 25
$735.6M
Q1 25
$798.2M
$730.6M
Q4 24
$835.2M
$664.6M
Q3 24
$827.3M
$667.8M
Q2 24
$645.1M
Q1 24
$836.1M
$638.7M
Debt / Equity
BIOX
BIOX
MUX
MUX
Q4 25
0.23×
Q3 25
0.26×
Q2 25
0.26×
Q1 25
0.26×
Q4 24
0.08×
Q3 24
0.06×
Q2 24
0.07×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
MUX
MUX
Operating Cash FlowLast quarter
$14.4M
$3.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
0.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
MUX
MUX
Q4 25
$3.1M
Q3 25
$14.4M
$5.2M
Q2 25
$478.0K
Q1 25
$23.3M
$-1.9M
Q4 24
$-5.4M
$-1.2M
Q3 24
$5.2M
$23.2M
Q2 24
$3.6M
Q1 24
$-17.4M
$3.9M
Cash Conversion
BIOX
BIOX
MUX
MUX
Q4 25
0.08×
Q3 25
Q2 25
0.16×
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons